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Abstract
Background: Identification of BRCA mutations in breast cancer (BC) patients influences treatment and survival and
may be of importance for their relatives. Testing is often restricted to women fulfilling high-risk criteria. However,
there is limited knowledge of the sensitivity of such a strategy, and of the clinical aspects of BC caused by BRCA
mutations in less selected BC cohorts. The aim of this report was to address these issues by evaluating the results
of BRCA testing of BC patients in South-Eastern Norway.
Methods: 1371 newly diagnosed BC patients were tested with sequencing and Multi Ligation Probe Amplification
(MLPA). Prevalence of mutations was calculated, and BC characteristics among carriers and non-carriers compared.
Sensitivity and specificity of common guidelines for BRCA testing to identify carriers was analyzed. Number of
identified female mutation positive relatives was evaluated.
Results: A pathogenic BRCA mutation was identified in 3.1%. Carriers differed from non-carriers in terms of age at
diagnosis, family history, grade, ER/PR-status, triple negativity (TNBC) and Ki67, but not in HER2 and TNM status. One
mutation positive female relative was identified per mutation positive BC patient. Using age of onset below 40 or
TNBC as criteria for testing identified 32-34% of carriers. Common guidelines for testing identified 45-90%, and
testing all below 60 years identified 90%. Thirty-seven percent of carriers had a family history of cancer that would
have qualified for predictive BRCA testing. A Variant of Uncertain Significance (VUS) was identified in 4.9%.
Conclusions: Mutation positive BC patients differed as a group from mutation negative. However, the commonly
used guidelines for testing were insufficient to detect all mutation carriers in the BC cohort. Thirty-seven percent
had a family history of cancer that would have qualified for predictive testing before they were diagnosed with BC.
Based on our combined observations, we suggest it is time to discuss whether all BC patients should be offered
BRCA testing, both to optimize treatment and improve survival for these women, but also to enable identification
of healthy mutation carriers within their families. Health services need to be aware of referral possibility for healthy
women with cancer in their family.
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Background
Germline mutations in the BRCA1 and BRCA2 genes
are associated with a high lifetime risk of breast and
ovarian cancer [1, 2]. Knowledge of one’s BRCA status is
of importance for healthy women as cancer may be pre-
vented through risk-reducing mastectomy and salpingo-
oophorectomy [3–5]. Identification of a pathogenic
BRCA mutation in a woman diagnosed with breast can-
cer (BC) may influence treatment and prognosis of her
current cancer but also enable prevention of future can-
cers [6–12]. Consequently, surgeons and oncologists
more and more frequently want to offer genetic testing
at time of diagnosis.
Because of the high costs associated with genetic ana-
lyses, BRCA1/2- testing has traditionally been restricted to
BC patients having an a priori high risk of being a carrier.
These factors include young age at diagnosis (below
45 years), triple-negative breast cancer (TNBC) or a family
history of breast- and/or ovarian cancer [13–22]. The
American Society of Clinical Oncology (ASCO), The Na-
tional Comprehensive Cancer Network (NCCN) in the US
and the Norwegian Breast Cancer Group (NBCG) all have
guidelines for BRCA testing of BC patients based on these
risk factors (Additional file 1: Figure S1), and according to
The National Institute for Health and Care Excellence
(NICE) in the UK, BRCA testing should be offered to BC
patients with a probability of having a mutation is 10% or
more [23–26]. There are also corresponding guidelines for
predictive testing of healthy women.
During the recent years, the cost of genetic testing has
decreased due to the advent of new and more efficient
DNA-sequencing technologies. Consequently, BC pa-
tients are now often offered multi gene panel testing.
These panels include BRCA1/2 and the other high risk
breast cancer genes TP53 and PTEN, but also genes with
more moderate cancer risk and genes whose clinical sig-
nificance is still not resolved [27, 28]. Testing is never-
theless still mostly restricted to patients fulfilling certain
high risk criteria for being mutation carriers, and few
studies have described BRCA testing of unselected
groups of BC patients [29–35]. To our knowledge, only
two studies have performed testing with sequencing and
Multi-Ligation Probe Amplification (MLPA) of all pa-
tients included [30, 35]. Knowledge of the clinical char-
acteristics of BC caused by BRCA mutations in
unselected BC cohorts is therefore limited. Moreover,
there is also limited information about the sensitivity
and specificity of current guidelines for BRCA testing to
identify carriers in cohorts not selected for high risk fac-
tors. With the ongoing changes in opportunities for gen-
etic testing we believe it is necessary to assess whether
the current strategies for BRCA testing are sufficient to
enable mutation positive women to benefit from the po-
tential of both cancer cure and prevention that lies
within such testing. Observations from BRCA testing of
less selected groups of BC patients are necessary for this
evaluation.
The NBCG guidelines used in Norway are regularly re-
vised. Because it became clear that identification of a
BRCA mutation could have implications for treatment, a
subjective criteria was introduced a few years ago. If the
treating physician considered the test result to be of im-
portance for treatment decisions, testing could be of-
fered even in the absence of other high risk factors such
as young age or family clustering. As a consequence,
testing could be offered also to BC patients with an a
priori low risk of being carriers. Due to this change in
practice we have been able to compare the sensitivity of
previous and present national and international guide-
lines for BRCA testing in BC patients without the selec-
tion bias described.
This report summarizes the results of BRCA testing in
South-Eastern Norway according to these revised
Norwegian guidelines from 1st of January 2014 to 31st
of August 2015. The study had three specific aims:
Firstly, it was to calculate the prevalence of BRCA muta-
tions in this cohort of BC patients that as a whole had
an a priori low risk of being mutation carriers, describe
the spectrum of mutations, and the number of mutation
positive female relatives identified. Secondly, we wanted
to describe and compare clinicopathological features of
BC among carriers and non-carriers. The third aim was
to calculate the sensitivity and specificity of different
guidelines used for diagnostic testing [23–26], and also
to evaluate how many mutation carriers that had a fam-
ily history of cancer that qualified for predictive testing
before they were diagnosed with BC [26].
Methods
Patients
During the study period, a total of 1371 BC patients
were tested. Two cohorts of patients are described in
this report: Cohort 1: Patients tested at The Breast
Cancer Surgery Unit, Department of Oncology, Oslo
University Hospital, Ullevål (OUH-U), and Cohort 2: Pa-
tients tested at the other hospitals in the health adminis-
trative area of South Eastern Norway called South-
Eastern Norway Regional Health Authority trust. This
cohort is referred to as SERHA.
OUH-U (cohort 1)
This is the largest unit treating BC patients in Norway.
Six hundred and seven patients underwent BC surgery,
and 440 (72.5%) of them were tested. Two of these were
men. A quality of care database was established at the
unit to evaluate the practice of BRCA testing among this
group of patients. Information on age of onset, receptor
status, grade, stage, nodal involvement, Ki67 and family
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history was accessed from the Electronic Patient Record
(EPR) system (DIPS®) and registered in the quality data-
base. Family history was taken by the doctor admitting
the patient to the hospital according to ordinary rou-
tines. No standardized or quality assured methods were
used. The information on family history recorded in the
patient record of both carriers and non-carriers was
evaluated and scored according to the old diagnostic
and predictive test criteria of NBCG [26]. No informa-
tion on size (number of family members) of the families
was recorded. One hundred and sixty-seven patients
were not tested. Of these, 96 either directly declined
testing or wanted to think about it. For the remaining
71, there was no record in the hospital’s EPR system on
whether testing was offered or not.
SERHA (cohort 2)
We do not have the exact number of all BC patients
undergoing treatment at these hospitals the other hospi-
tals in the health region during the study period, but
based on numbers from the Norwegian Breast Cancer
Registry (NBCR) at the Cancer Registry of Norway
(CRN) we estimated that the number was around 2400
[36]. Nine hundred and thirty-one (39.0%) were tested.
Information on age of onset, receptor status and family
history was registered on all carriers in the EPR at the
Department of Medical Genetics (DMG) OUH. No in-
formation was collected on mutation negatives in this
cohort.
Genetic testing
Genomic DNA was purified from EDTA-anticoagulated
blood using the QiaSymphony instrument (Qiagen,
Hilden, Germany). All 23 coding exons of BRCA1 (exons
2 to 24) and 26 coding exons of BRCA2 (exons 2 to 27),
were amplified, the primers were designed to cover all
coding exons and adjacent 20–base pair introns. The
amplified DNA fragments were sequenced using the Big-
DyeTerminator Cycle Sequencing kit on an ABI 3730
DNA Analyzer (Applied Biosystems, Foster City, CA).
All sequences were compared with the BRCA1
(NM_007294.3) and BRCA2 (NM_000059.3) reference
sequences for variant detection. In addition, MLPA
(P002 BRCA1 and P045 BRCA2 MLPA probe mixes;
MRC-Holland, Amsterdam, The Netherlands) was per-
formed to identify deletions and insertions.
Results were interpreted and reported following the
recommendations of the American College of Medical
Genetics [37], using the five-class system. Patients with a
variant class 4 or 5, patients with a normal test, but with
a young age of onset and/or a family history of BC, and
patients with a Variant of Uncertain Significance (VUS)
were all referred to genetic counseling at DMG OUH.
Here, they received genetic counseling, a detailed family
history was obtained and relevant diagnoses in relatives
confirmed. A quality of care database was established at
DMG OUH and all BC patients with a pathogenic BRCA
mutation and their relatives who were tested for the mu-
tation were registered here. Both male and female rela-
tives of the mutation positive BC patients were offered
testing for the mutation in question. Testing was offered
not only to first degree relatives, but to all blood rela-
tives who were referred to DMG OUH.
Statistics
Mutation carriers from both cohorts were scored ac-
cording to the ASCO, NCCN, NICE and NBCG guide-
lines [23–26]. Carriers were scored according to the
NBCG criteria as they were before the revision that
opened for testing based on implication for treatment
decisions. In the remainder of the article these will be
referred to as the “old NBCG criteria”. To score patients
according to the NICE guidelines, the BOADICEA Web
Application (BWA v3) [38] was used to calculate risk of
carrying a BRCA mutation. Sensitivities of criteria to
identify carriers were calculated excluding the patients
with a known family mutation.
Tests for trends were performed to compare the differ-
ences in BC characteristics between mutation carriers
and non-carriers. Separate analyses were done to com-
pare tested and non-tested in order to illustrate potential
bias in the group that was not tested. Mutation positives
in Cohort 1 and 2 were compared to investigate how
similar the two cohorts were. Pearson’s Chi square and
one-way ANOVA were used to compare categorical
variables (ER, PR, HER2 status, grade, stage, nodal in-
volvement, family history, Ki67 ≥ 30%) while independ-
ent t-tests were used to compare continuous variables
(age, mean Ki67). In all analyses, p-values less than 0.05
were considered statistically significant. All statistical
analyses were performed using SPSS version 21.0. When
missing values were observed, this case was omitted in
the analysis of this variable.
Results
Identified mutation carriers, spectrum and frequency of
mutations
A pathogenic mutation in BRCA1/2 was identified in
42 of the 1371 (3.1%) BC patients. Thirteen mutation
carriers were identified in Cohort 1 (13/400 = 3.0%),
and 29 in Cohort 2 (29/931 = 3.1%). All mutation
carriers were women. Twenty-eight (2.0%) had a mu-
tation in BRCA1 and 14 (1.0%) in BRCA2. Median
and mean age at diagnosis was 45 years (range 26-
77 years) and 46.1 years (46.3 years for BRCA1 and
45.6 years for BRCA2) respectively. Four of the 42
women belonged to families where a BRCA mutation
already had been detected, but had not sought
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predictive genetic testing. Four of the mutation car-
riers were detected through MLPA (dup exon 3-16,
dup exon 13 and del exon 22 in BRCA1 and dup
exon 20 in BRCA2), and the remaining carriers with
sequencing. A VUS was identified in 67 (4.9%)
patients.
When considering only those with Norwegian ances-
try, we revealed that 13/29 (44.8%) had one of the
known Norwegian founder mutations [39]. Eleven of 29
(37.9%) had a mutation previously found in 1- 9 families
at DMG (unpublished data), and 5/29 (17.2%) had a mu-
tation not previously observed in Norway. One of these
was BRCA2 c.614delG. Two patients carried this muta-
tion and were related. Of the 13 mutation carriers that
were not of Norwegian ancestry, three were from Poland
and two from Morocco. The following nationalities were
represented with one carrier each: Canadian, Swedish,
Iraqi, Latvian, Indian, Turkish, and Greek. Three differ-
ent BRCA2 mutations were identified in the three BC
patients from Poland. None of them were among the
mutations known to be frequent in the Polish population
[40–42], and only one of them had been reported previ-
ously (c.9403delC) [42]. The other two (c.4797_4797del-
CAAT and c.7024C > T) were not found to be reported
previously in the Polish population. Mutation, age of on-
set, nationality, fulfilling criteria for predictive testing or
not and clinicopathological aspects of tumors among
mutation carriers is presented in Table 1. Age at diagno-
sis is given in age ranges to prevent disclosing patient
information.
As of August 2016, 67 female and 19 male relatives of
the 42 mutation positive BC patients have been tested for
the mutation identified in their family. Forty female rela-
tives have tested positive for the mutation identified in
their family. Five of the 42 BC patients had no adult fe-
male relatives living in Norway. Excluding these 5, 40/
37 = 1.1 female mutation positive female relative has so
far been identified per mutation positive BC patient. This
number is likely to increase as more relatives are informed
and tested. The mean age in this group of carriers was
46.7 years (range 20-84). All were offered annual MRI and
mammography from the age of 25, and they were given
the opportunity of choosing risk-reducing surgery. Seven
of the relatives had already had cancer before the muta-
tion was identified in their relative. Five of these had had
BC and two OC. In addition, after being tested for the
mutation in their family, one woman has been diagnosed
with BC at first MRI and one has been diagnosed with OC
with FIGO stage 1B when undergoing prophylactic
salpingo-oophorectomy. In addition to those who have
been tested, 37 female relatives (first degree or second de-
gree through a man) aged above 18 years and 17 below
18 years have been identified, but they have not yet been
referred for testing.
Comparison of clinicopathological characteristics of
tumors in mutation positive and mutation negative from
the OUH-U cohort
No information was collected about the mutation nega-
tive BC patients in Cohort 2 from SERHA. A detailed
comparison of the clinicopathological characteristics of
tumors in mutation positive and mutation negative was
therefore only possible to perform in cohort 1 from
OUH-U. The results are presented in Table 2. Compared
to the mutation negative, mutation positive women were
younger (p < 0.001), had tumors of higher grade
(p = 0.001), higher Ki67 (p < 0.001 (comparing mean)
and p = 0.004 (comparing number with <30% activity)
and more of them had TNBC (p < 0.001). In addition,
more mutation carriers had family histories of breast
and/or ovarian cancer compared to BC patients without
mutation (p = 0.035). No significant difference was ob-
served in TNM- status (p = 0.396) and HER2-profile
(p = 0.84). In cohort 1 from OUH-U, 167 patients
were not tested. They had a higher age at diagnosis
(p < 0.001), a lower Ki67 score (p < 0.05) and a lower
proportion fulfilled the old NBCG criteria (p < 0.05)
compared to the patients tested (Additional file 2:
Table S1).
To indirectly assess whether the two cohorts were
similar in terms of risk distribution, we compared muta-
tion positive patients in the two groups in terms of age
at diagnosis, receptor status and family history of cancer.
There was a tendency towards a higher mean age of on-
set in Cohort 2 compared to Cohort 1 (48 vs 42,
p = 0.09). There was no significant difference in terms of
TNBC and whether or not they fulfilled the diagnostic
NBCG criteria (Additional file 3: Table S2).
Sensitivity and specificity of criteria for genetic testing
The old NBCG, the NCCN, and ASCO guidelines had a
sensitivity ranging from 84.2% to 89.5%. The NICE
guidelines had the lowest sensitivity, and would have
identified only 44.7% of the mutation positive women.
Testing only women below 40 years or only those with
TNBC would have identified 31.6% and 34.2% of the
mutation carriers. Testing all BC patients below 60 years
would have identified 89.5%. Almost 40% of the BC pa-
tients found to carry a BRCA mutation had a family his-
tory of cancer that fulfilled the NBCG criteria for
predictive BRCA testing, before they were diagnosed
with BC themselves. See Table 3 for details.
The specificity of the different criteria for testing was
calculated for Cohort 1 from OUH, and is presented in
Table 4. The highest specificity was found for the high-
risk criteria separately of each other. Breast cancer
<40 years of age and TNBC both had a specificity of
94%. The specificity of fulfilling the NBCG criteria was
70%, while having breast cancer below 60 years of age
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Table 1 Identified BRCA1/2 carriers








BRCA1 1 c.2019delA Frameshift 20-29 No No Yes
1 c.1016dupAa Frameshift 30-39 Yes Yes Yes
1 del exon 3-16 Deletion 30-39 No No No
1 c.3228_3229delAGa* Frameshift 30-39 Yes No No
1 c.3178G > Ta Nonsense 40-49 Yes No No
1 c.3084_3094delTAATAACATTAa Frameshift 40-49 Yes No Yes
1 c.3228_3229delAGa Frameshift 40-49 Yes No Yes
1 c.5047G > Tb Nonsense 40-49 Yes Yes Yes
1 c.3607C > Tb Nonsense 50-59 Yes Yes No
1 c.4484G > Ac Missense. Leads to
skipping of exon 14
50-59 Yes No No
2 c.5407-2A > Gc Frameshift, skipping
of exon 23
60-69 Yes No No
2 c.1072delCb Frameshift 60-69 Yes No No
2 c.1556delAa Frameshift 40-49 Yes Yes No
2 c.5153G > Cb Missense 40-49 Yes Yes No
2 c.3756_3759delGTCT Frameshift 40-49 No No No
2 del exon 22 Frameshift 40-49 No No Yes
2 c.5309G > T Missense 30-39 No Yes Yes
2 c.697delGTa Frameshift 70- Yes Yes Yes
2 c.3228_3229delAGa Frameshift 50-59 Yes Yes Yes
2 c.445G > T Nonsense 40-49 No Yes Yes
2 c.1016dupAa Frameshift 50-59 Yes No Yes
2 c.5266dupC Frameshift 30-39 No Yes No
2 c.2989_29x0dupb Frameshift 50-59 Yes No No
2 c.1016dupAa Frameshift 30-39 Yes No No
2 c.1556delAa Frameshift 50-59 Yes Yes No
2 dup exon 13b Frameshift 50-59 Yes No No
2 c.5309G > T Missense 30-39 No No Yes
2 c.5503C > T Nonsense 50-59 No Yes Yes
BRCA2
1 c.4710delA Frameshift 30-39 No No No
1 c.3847_3848delGTa Frameshift 40-49 Yes No No
1 c.614delGc Frameshift 50-59 Yes Yes No
2 c.4936_4939delGAAAb Frameshift 40-49 Yes No No
2 c.3847delGTa Frameshift 40-49 Yes No No
2 c.9403delC Frameshift 40-49 No No No
2 c.5722delCTb Frameshift 40-49 Yes No No
2 c.6059_6062delAACAb Frameshift 30-39 Yes No No
2 c.5722delCTb Frameshift 50-59 Yes Yes No
2 c.4794_4797delCAAT Frameshift 40-49 No Yes No
2 c.614delGc Frameshift 30-39 Yes Yes No
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had a specificity of 48%. Mutation frequency and num-
ber needed to test (NNT) to identify one mutation car-
rier depending on different test criteria are shown in
Table 5. Testing all BC patients below 60 years would
give mutation frequency of 5.5% and by using this cri-
teria, 18 BC patients had to be tested to identify one
carrier.
Discussion
We have reported the results of diagnostic BRCA testing
of women diagnosed with BC in the South-Eastern part
of Norway according to the NBCG guidelines. These
guidelines opened up for testing independently of the
common high risk factors i.e. also when the treating
physician considered the test result to be of importance
for treatment decisions. To our knowledge, this is there-
fore the largest and least selected series reported where
BC patients were tested with both sequencing and
MLPA of both genes, and it does not have the selection
bias arising when only high-risk patients are tested.
We identified a mutation in 3.1% of BC patients. In a
recent study from the Western region of Norway,
405 BC patients were tested for 30 specific BRCA1/2
mutations and with MLPA [32]. Sequencing was per-
formed on 94 of these. A mutation was found in only
1.7% of participants. Both studies are small and conse-
quently they do have limitations. However, the observed
difference may at least partly be explained by the fact
that all patients in our study were tested with sequen-
cing and MLPA and not for selected mutations only. In
our study, 16 out of 29 (55%) women with Norwegian
ancestry did not have any of the 10 most common
Norwegian founder mutations [39], and five (17%) had a
mutation that had not been previously observed in our
population. In comparison, in 2007 the 10 founder mu-
tations accounted for about two-thirds of all detected
mutation carriers at our department [39]. This reflects
that in 2007 most patients were tested for a limited
number of mutations, whereas today sequencing and
MLPA is offered to all who qualify for testing in our
health region. Our findings also illustrate that there are
mutations within our population that are and may re-
main rare. By testing only for frequently observed
mutations in the Norwegian population, a substantial
number of mutation positive women with a pathogenic
BRCA mutation will not be found.
A VUS was identified in 4.9% of the tested patients.
Our numbers are comparable to what others have re-
vealed [43]. Studies have reported that physicians, with
limited formal training in genetics, may misinterpret
VUS results [44–46]. This was dealt with in the current
study as all patients with a VUS were referred to genetic
counseling. There is a worry that information about a
VUS may have a negative psychological impact on the
patient [47]. However, studies have also demonstrated
that it is interpreted as more similar to a test result
where no pathogenic variant has been detected than to a
result with an identified pathogenic variant [46]. Ad-
dressing the issue of patients’ interpretation of risk and
possible psychological impact was beyond the scope of
this study, but should be closer evaluated in future stud-
ies. By offering testing only for a set of already known and
described mutations one would avoid the challenges asso-
ciated with identifying VUS. We have however described
that a substantial number of mutation carriers will be
missed by testing only for known mutations. It is our
opinion that the benefits associated with identifying all
carriers (and the corresponding risk associated with not
identifying a mutation carrier) outweigh the current chal-
lenges associated with identifying VUS. One may also
hypothesize that the frequency of VUS may decrease in
the future as more people are undergoing testing.
By comparing carriers and non-carriers tested at
OUH-U we observed that even though testing was of-
fered broadly, mutation positive women still differed
from mutation negative in terms of the known high risk
aspects for being carriers: age of onset, triple negativity
and family history. We found no difference in HER2-
status between the two groups, and these findings are in
accordance with a recent study where HER2-status was
not found to be a reliable predictor of BRCA-status [48].
Mutation carriers had a higher score for Ki67 than mu-
tation negatives, and this has also been described in a
few studies [49, 50]. The observed differences between
the two groups are also illustrated by the fact that each
of the test criteria has a high specificity (see Table 4).
Table 1 Identified BRCA1/2 carriers (Continued)
2 c.7024C > T Nonsense 30-39 No Yes No
2 c.9699_9702delTATGc Frameshift 70- Yes No No
2 dup exon 20b Frameshift 40-49 Yes Yes Yes
1: Tested at Oslo University Hospital Ullevål (OUH-U)
2: Tested at other hospitals in South-Eastern Norway Regional Health Authority trust’s coverage area (SERHA)
aCommon Norwegian founder mutation38
bIdentified in 1-9 families at Department of Medical Genetics (DMG), OUH (unpublished data)
cNot identified previously at DMG, OUH
BC Breast cancer
OC Ovarian cancer
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Whereas the mutation positive differed as a group
from mutation negative, selecting patients for testing
based on the known high risk factors will identify
carriers with varying sensitivity (see Table 3). Testing
only those with BC below 40 years or TNBC identified
31.6% and 34.2% of carriers respectively, and less than







Below 40 years 5 (38.5%) 24 (5.6%)
Below 50 years 10 (76.9%) 106 (24.8%)
Below 60 years 13 (100%) 222 (52.0%)
Age at diagnosis
Mean (95% CI) 42 (36.1-47.9) 57.9 (56.8-59.1) <0.001
Median (range) 43 (26-58) 58 (23-93)
Predictive test criteria fulfilled 4 (30.8%) 49 (11.5%) 0.035
Stringent NBCG criteria fulfilled 12 (92.3%) 130 (30.4%) <0.001
TNM (n = 13) (n = 422)
T1 5 (38.5%) 261 (61.8%)
T2 5 (38.5%) 121 (28.7%) 0.396
T3 2 (15.3%) 26 (6.2%)
T4 1 (7.7%) 13 (3.1%)
N0 8 (61.5%) 295 (72.0%)
N1 2(15.4%) 82 (19.4%) 0.078
N2 3(23.1%) 24 (5.7%)
N3 0 12 (2.8%)
Distant metastasis 0 2 (0.5%) 0.76
Grade (n = 13) (n = 419)
1 0 101 (24.1%) 0.001
2 4 (30.8%) 211 (50.4%)
3 9 (69.2%) 107 (25.5%)
Estrogen receptor status (n = 13) (n = 423)
Positive 7 (53.8%) 371 (87.7%) <0.001
Negative 6 (46.2%) 52 (12.3%)
Progesterone receptor status (n = 13) (n = 422) 0.045
Positive 5 (38.5%) 276 (65.4%)
Negative 8 (61.5%) 146 (34.6%)
HER2 status (n = 13) (n = 423)
Positive 2 (15.4%) 57 (13.5%) 0.84
Negative 11 (84.6%) 366 (86.5%)
Triple negative breast cancer (n = 13) (n = 422)
5 (38.5%) 30 (7.1%) <0.001
Ki67 (n = 13) (n = 412)
Mean (95% CI) 59 (45.3-72.8) 31.3 (29-33) <0.001
< 30% activity 11 (84.6%) 182 (44.1%) 0.004
NBCG Norwegian Breast Cancer Group
TNM Scoring of tumors according to the TNM Classification of Malignant Tumors
T Size of original tumor
N Involvement of regional lymph nodes
M Distant metastasis
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50% of carriers qualified for testing according to the
NICE guidelines. By use of the comprehensive ASCO,
NCCN and old NBCG criteria, where the different single
characteristics are combined in order to increase sensi-
tivity, between 84.2 and 89.5% would be identified.
NBCG has recently suggested that testing should be of-
fered to women with TNBC under the age of 60 [26]. By
adding this aspect to the original stringent criteria, 34/
38 (89.5%) would have been identified. In a recent study
where 488 women with BC were tested for mutations in
25 cancer susceptibility genes, Tung et al. found that all
BRCA-mutation carriers fulfilled the NCCN guidelines
[35]. We do not know whether the difference in ob-
served sensitivity is due to chance or systematic differ-
ences between the two cohorts.
The ASCO, NCCN and NBCG criteria include an as-
sessment of the patient’s family history of cancer. The
family histories of the mutation positive BC patients
identified in our study were thoroughly investigated by
genetic counselors and medical geneticists following the
identification of the mutation, resulting in the sensitivity
estimates presented. The observed estimates may there-
fore be higher than what is realistic in the clinical setting
when family history is taken by the admitting physician
at time of diagnosis. It may be difficult for the patient to
know or recall detailed information about their family
history of cancer when asked in a possibly stressful diag-
nostic setting. In line with this, Høberg-Vetti et al. found
in their study from the Western part of Norway that 2
out of 26 (7.7%) mutation carriers reported a negative
family history of cancer at time of diagnosis and testing,
but closer evaluation revealed that they did have a family
history of breast and/or ovarian cancer [32]. We also
worry that the complexity of the NCCN, ASCO and
NBCG criteria make them difficult to use and imple-
ment systematically in a busy clinical setting. Both these
aspects could lead to fewer patients being offered test-
ing, even those fulfilling the criteria. This is illustrated in
several studies. Febbraro and colleagues observed that
only 34% of breast cancer patients fulfilling NCCN
guidelines were referred to genetic counseling and test-
ing [51]. In a recent Swedish study where all BC patients
were tested retrospectively, it was found that 65% of the
mutation carriers fulfilled Swedish criteria for testing,
but only 18% had been identified in regular clinical rou-
tine [52]. Moreover, even though all mutation carriers
fulfilled the NCCN criteria in the study by Tung et al.,
13.3% of the carriers identified through this research
project had not been tested clinically [35].
The fact that 37% of the women had a family history
of cancer that according to the Norwegian guidelines
qualified for referral to predictive genetic testing before
their own disease, may be another illustration of the
challenges with using assessment of family history as a
criteria for genetic testing or referral to genetic counsel-
ing. The low number leads us to conclude that the
current system of referring healthy women to genetic
testing based on their family history is suffering from
lack of compliance. These women contracted cancers
that could have been prevented had they known about
their risk and undergone prophylactic surgery. The
Table 3 Sensitivity of criteria for testing to identify BRCA1/2
carriers
Test criteria BRCA1/2 mutation
carriers
(n = 38a)
BC <40 years 12 (31.6%)
BC <50 years 28 (73.7%)
BC <60 years 34 (89.5%)
TNBC 13 (34.2%)
Fulfilling stringent NBCG criteria for testing 32 (84.2%)
Fulfilling ASCO guidelines for testing 34 (89.5%)
Fulfilling NICE guidelines for testing 17 (44.7%)
Fulfilling NCCN criteria for testing 32 (88.9%)
Family history fulfilling NBCG criteria for predictive
testing before index person contracted BC
14 (36.8%)
aThe four women belonging to families where a mutation had already been
identified were excluded from this analysis
BC Breast cancer
TNBC Triple Negative Breast Cancer
NBCG Norwegian Breast Cancer Group
ASCO American Society of Clinical Oncology
NICE National Institute for Health and Care Excellence
NCCN The National Comprehensive Cancer Network
Table 4 Specificity of criteria for BRCA1/2 testing
Test criteria Specificitya
BC < 40 years (403/427) 94.4%
BC < 50 years (321/427) 75.2%
BC < 60 years (205/427) 48%
TNBC (397/422) 94.1%
Fulfilling NBCG criteria for diagnostic testing (297/427) 69.5%
Fulfilling NBCG criteria for predictive testing (378/427) 89%
aSpecificity is calculated only for Cohort 1, OUH-U
BC Breast cancer
TNBC Triple negative breast cancer
NBCG Norwegian breast cancer group
Table 5 Number needed to test to identify one mutation
carrier according to test criteria
Test criteria Mutation frequency Number needed to test
(NNT) to identify one
mutation carrier
BC < 50 years 10/116 = 8.6% 12
BC < 60 years 13/235 = 5.5% 18
TNBC 5/35 = 14% 7
NBCG criteria 12/147 = 8.2% 12
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reasons for this lack of referral and how it can be im-
proved need to be further explored, but this was not the
scope of the current study.
Using age of onset as a criteria for testing will likely
lead to increased adherence by surgeons and oncologists
compared to guidelines requiring a detailed and compli-
cated assessment of the patient’s family history of cancer.
Testing all BC patients below 60 years identified as
many or more carriers than all guidelines assessed (see
Table 3). Due to the lowered cost of testing and the clin-
ical impact of detecting a BRCA mutation, Finch et al.
[53] have recently argued that the threshold for testing
should be lowered from a 10% prior probability of being
a carrier to 5%. Testing all under 60 in the OUH-U co-
hort gave a mutation detection rate of 5.5% (see Table
5), i.e. within this threshold. By using this criteria one
would have to test 18 BC patients to identify one carrier.
As of August 2016, testing these 18 patients had also led
to the identification of one female relative per index pa-
tient. In Cohort 1 from OUH-U, 235 out of the 440
tested (53.4%) were younger than 60 and 132/440 (30%)
fulfilled the old NBCG criteria (see Table 2). In 2014,
3324 Norwegian women contracted BC [54]. Using the
calculations from the OUH-U cohort indicate that test-
ing all below 60 years will involve 800 more analyses an-
nually compared to testing only those fulfilling the old
NBCG criteria.
One year after the last BC patient in our cohort was
tested, 1.1 female relative per identified carrier had
tested positive for the mutation and were given the op-
portunity of cancer prevention. It is likely that this num-
ber will increase as more relatives are informed and
tested. According to Finch et al., “the value of a cancer
genetic testing program comes from the number of can-
cers prevented” [53]. Even though testing all below
60 years may be feasible and effective, we observed that
10% will still be missed by this strategy. Two mutation
carriers were older than 70 years. One may argue that
the identification of a mutation in a woman who is
70 years or older may not influence treatment decisions,
life expectancy or lead to a significant gain in quality ad-
justed life years (QALY) for this woman. However, it is
likely that women over 70 have adult female relatives
that may be at high risk of cancer due to the mutation.
We observed that more than half of the mutation car-
riers did not have a family history of breast and/or ovar-
ian cancer before they were diagnosed with breast
cancer themselves. These findings are in line with other
studies reporting that family history has limited value in
predicting carrier status [33, 38, 55], and our findings il-
lustrate the difficulties with finding these women prior
to disease development. Today, these women cannot ob-
tain genetic testing while still healthy, as a population-
based screening protocol is not accessible. Mary Claire
King and colleagues consider that the identification of “a
woman as a carrier only after she develops cancer is a fail-
ure of cancer prevention” [56] and based on their finding
that BRCA mutation carriers have a high risk of cancer re-
gardless of their family history [57], argue for population
based screening to all women aged 30 years [56].
In a cost analysis of the cancer genetic services in
the UK, Slade et al. have demonstrated that the most
cost efficient genetic service model is to identify un-
affected mutation carriers through an affected muta-
tion positive index person [58], and argue for more
comprehensive testing of all cancer patients fulfilling
the NICE criteria. Patients fulfilling these criteria have
an a priori 10% risk of being carriers. We identified a
mutation in 3.1% of carriers, and one may argue that
this is too low to warrant testing of all BC patients.
We have however, recently shown that the practice of
BRCA testing at OUH-U is cost-effective within the
frequently used thresholds in Norway [59]. The cost-
effectiveness was mainly due to the prevented breast-
and ovarian cancers in their female relatives who
tested positive for the mutation. Possible life years
gained (LYG) due to prophylactic surgery among the
BC patients was not included in the calculations in
this study. The calculations may therefore be consid-
ered a conservative estimate. In addition, the cost of
testing is constantly dropping, making the cost-
effectiveness of a broad application of BRCA testing
to BC patients even larger in the coming years.
Our results indicate that by testing only for founder
mutations in the BC population of the South-Eastern
part of Norway, and by testing only those with a family
history of cancer, a significant number of mutation car-
riers will be missed. One may ask whether these results
are relevant for screening strategies in other populations.
The prevalence of BRCA mutations vary between popu-
lations [34, 60, 61], and the indication for genetic
screening of all breast and ovarian cancer patients may
be stronger in populations with a higher frequency of
mutation carriers than in Norway. In populations where
there is a stronger founder effect, the number of muta-
tion carriers missed by offering testing for only founder
mutations will be lower than what we have observed.
However, recent studies have demonstrated that 13% of
BRCA1 mutations and 7.2% of BRCA2 mutations in
Ashkenazi Jews were non-founders [62]. Similarly, a
Polish study found that in families with a family history
of breast and/or ovarian cancer having tested negative
for Polish BRCA founder mutations, sequencing revealed
31 other BRCA mutations. The detection rate of these
mutations was 10% [63]. Sequencing and MLPA may
therefore be warranted also in populations with a stron-
ger founder effect than in Norway. We observed that
only 40% of mutation carriers had a family history of
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breast and/or ovarian cancer. There are various reasons
for this: Small family size, mutations may be inherited
through several generations of men and incomplete
penetrance. Family history as a selection tool for testing
may have a higher sensitivity in populations with higher
birth rates than in Norway. However, most western
countries have had a declining birth rate since the 1960s
and now have a birth rate between 1.5 and 2 [64]. One
may therefore hypothesize that the value of using family
history as a selection tool for testing will be even lower
in the future.
BC patients are now often offered multi gene panel
tests, and this is the direction in which the field of
genetic testing is moving rapidly. There are several
advantages with this strategy compared to testing only
for the BRCA genes. More carriers of pathogenic mu-
tations in other known BC risk genes such TP53,
PTEN or PALB2 will be identified. In addition, car-
riers of mutations in genes that likely would not have
been investigated when testing only for one gene at a
time will be identified. By testing a sequential series
of breast cancer patients for 25 cancer predisposition
genes, Tung and colleagues identified carriers of mu-
tations in the MSH6 and PMS2 genes [35]. Con-
versely, by testing families suspected to have Lynch
Syndrome for 112 known or candidate colorectal can-
cer genes, Hansen and colleagues identified one
BRCA1 carrier and two BRCA2 carriers [65]. In sum,
through multi gene panel testing more mutation car-
riers and their mutation positive relatives will be
identified and given the opportunity of appropriate
cancer surveillance and/or prevention. In the coming
years this technology will also likely become more
cost effective than traditional Sanger sequencing of
one gene at a time. The aim of this study was not to
argue against the value of multi gene panel testing,
but rather to investigate whether the current strat-
egies for BRCA testing, regardless of technology used,
are sufficient to identify all carriers of mutations in
these well-known and defined genes.
One limitation to our study is that we have not
tested all BC patients. In the OUH-U cohort (Cohort
1) 167/607 = 27.5% of all women diagnosed with BC
were not tested. These women were older and fewer
filled the NBCG criteria than those who were tested.
Unfortunately, we do not have access to the exact
number of untested patients in the SERHA series or
clinical information about these. If 2400 were treated
in SERHA in the study period, about 39% of these
(931/2400) were tested. The reason for the lower
number of tested in Cohort 2 may be that there was
a lower awareness of the possibility of genetic testing
at these hospitals, but we cannot exclude that this co-
hort may be more selected. To assess this, we
compared the two cohorts indirectly by comparing
the mutation positive BC patients. There was a ten-
dency towards a higher age of onset in Cohort 2 from
SERHA, but this difference was not statistically sig-
nificant. No significant differences were found be-
tween mutation carriers in the two cohorts in terms
of TNBC and family history (Additional file 3: Table
S2). We also observed the same frequency of muta-
tion carries in the two series. The two cohorts may
therefore be similar, and it is likely that the untested
in Cohort 2 were older and that fewer filled the
NBCG criteria than the tested. If there are mutation
carriers among the untested in both series, the total
frequency of carriers might have been lower, but it is
likely that even fewer would have fulfilled the differ-
ent high-risk criteria.
Conclusions
By offering BRCA testing to a broad group of BC pa-
tients we found that 3.1% carried a deleterious muta-
tion, and so far this has led to the identification of
1.1 female mutation positive relative per mutation
positive BC patient. Even though mutation carriers
differed as a group from mutation negative, criteria
for testing based on the high-risk aspects did not de-
tect all BRCA carriers in this BC population. Testing
all BC patients below 60 years had a sensitivity
matching the commonly used guidelines, and
will likely be easier to apply, but 10% of mutation
carriers would still be missed. Thirty-seven percent of
the women had a family history of cancer prior to
their own BC that qualified for predictive genetic
testing. They contracted cancers that could have been
prevented if the health care system had identified
their increased genetic risk. Based on our combined
observations, we conclude that the current strategies
for BRCA testing are insufficient to detect all carriers.
We suggest that it is time to discuss whether BRCA
testing should be offered also to BC patients not be-
longing to a high risk group. If all BC patients are of-
fered BRCA testing, the potential for cancer cure and
prevention associated with such testing can be im-
proved even further than what today’s strategies for
testing allows. In case of lack of economic resources
to fulfill this strategy, at least those aged 60 years or
less at time of BC diagnosis should be tested. Our
observations also indicate that health services need to
be aware of referral possibilities for healthy women
with cancer in the family, and the reasons for the low
compliance should be explored. Improved strategies
both for diagnostic and predictive BRCA testing will
identify more mutation positive women prior to can-
cer development than the current practice.
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